Antibiotic Treatment Trial for Small Intestinal Bacterial Overgrowth

San Antonio Military Medical Center180 enrolled

Overview

This is a randomized, double-blind, placebo-controlled study to evaluate the efficacy of ciprofloxacin versus metronidazole versus placebo in eradication of small intestinal bacterial overgrowth (SIBO).

Approximately 180 study subjects with SIBO identified by positive glucose hydrogen breath (GHB) testing who meet inclusive and exclusive criteria will be randomized to receive either ciprofloxacin 500mg by mouth twice daily, metronidazole 500mg by mouth twice daily, or placebo by mouth twice daily. Subjects will complete a baseline symptom questionnaire and be treated for 14 days. Response will be assessed at end of treatment. The Gastrointestinal Symptom Rating Scale (GSRS) and GHB testing will be performed at the end of treatment. Subjects with a negative GHB at the end of treatment are considered as cured, or treatment success. Patients with treatment success will be reassessed for long-term response to treatment or disease recurrence at 30 days, 4 months, and 9 months using GHB. Symptoms will also be re-assessed at the 30 day, 4 month, and 9 month intervals with GSRS-IBS symptom questionnaire done prior to GHB testing.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

180

Conditions

Small Intestinal Bacterial Overgrowth

Interventions

MetronidazoleDRUG

Metronidazole 500mg given twice daily for 14 days

CiprofloxacinDRUG

Ciprofloxacin 500mg given twice daily for 14 days

PlaceboDRUG

Placebo given twice daily for 14 days

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients age greater than 18 who have been diagnosed with SIBO after a clinically indicated hydrogen breath test. * Patients with liver disease or liver cirrhosis will be included, as this particular group is at higher risk for developing SIBO, would potentially benefit from inclusion, and do not require dose adjustments with either study medication. * Patients on warfarin are not excluded, but INR will be uniformly recommended to be checked within 1 week of therapy initiation, as standard practice through the Coumadin clinic, for the potential effect on INR and increased risk of bleeding while on any antibiotic Exclusion Criteria: * Patient age less than 18 * Hypersensitivity to the antibiotics * Pregnancy or breast feeding * Patients who cannot consent for themselves * End stage renal disease defined as creatinine clearance \<30 mL/min or on hemodialysis. * Patients who have taken antibiotics in the past 30 days * Laxatives, stool softeners, or bulk fiber in the last 7 days * Enemas or suppositories in the last 3 daysⱡ

Outcomes

Primary Outcomes

Number of patients cured of SIBO after treatment with ciprofloxacin versus metronidazole versus placebo.

Time frame: 2 weeks

Secondary Outcomes

Gastrointestinal symptoms based on questionnaire

Time frame: Immediately post-treatment (approximately 2 weeks), 30 days, 4 months, and 9 months

Disease relapse rate of SIBO after treatment success

Time frame: Immediately post-treatment (approximately 2 weeks), 30 days, 4 months, and 9 months

Time interval between treatment success and recurrence of SIBO

Time frame: Immediately post-treatment (approximately 2 weeks), 30 days, 4 months, and 9 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.